✦ LIBER ✦

A phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer

✍ Scribed by Kiyoshi Mori; Suguru Machida; Takeshi Yoshida; Munehide Yoshida; Yasuliko Kano; Keigo Tominaga

Publisher: Springer
Year: 1999
Tongue: English
Weight: 68 KB
Volume: 43
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s002800050925

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I study of irinotecan and infusi

A phase I study of irinotecan and infusional cisplatin for advanced non-small-cell lung cancer

✍ K. Mori; Tsukasa Ohnishi; Kohki Yokoyama; Keigo Tominaga 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 128 KB

Phase II study of cisplatin as a 5-day c

Phase II study of cisplatin as a 5-day continuous infusion with vindesine plus recombinant human granulocyte-colony-stimulating factor in the treatment of advanced non-small-cell lung cancer

✍ Yoshikuni Saito; Kiyoshi Mori; Keigo Tominaga; Kouhei Yokoi; Naoto Miyazawa 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 500 KB

Phase II study of intensive chemotherapy

Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer

✍ Giorgio Vittorio Scagliotti; Umberto Ricardi; Lucio Crinó; Ernesto Maranzano; Fi 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 375 KB

Phase I/II study of carboplatin and oral

Phase I/II study of carboplatin and oral etoposide with granulocyte-colony stimulating factor in advanced nonsmall cell lung cancer

✍ Giuseppe Frasci; Giovanni Persico; Giuseppe Perillo; Giuseppe Comella; Pasquale 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 665 KB

Background. A combination of carboplatin (CBDCA) and oral etoposide is better tolerated than, and as effective as, more aggressive chemotherapy regimens in patients with advanced nonsmall cell lung cancer (NSCLC). A Phase 1/11 study was conducted to determine whether the addition of the granulocyte-

Docetaxel and granulocyte colony-stimula

Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial

✍ K. Alexopoulos; C. Kouroussis; N. Androulakis; E. Papadakis; M. Vaslamatzis; S. 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 90 KB

A phase I clinical and pharmacologic stu

A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma

✍ Hiroaki Okamoto; Akira Nagatomo; Hideo Kunitoh; Hiroshi Kunikane; Koshiro Watana 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 3 views

BACKGROUND. This Phase I study was designed to determine the toxicity and efficacy of a carboplatin and irinotecan (CPT-11) regimen with recombinant human granulocyte colony-stimulating factor (rhG-CSF) support for patients with advanced nonsmall cell lung carcinoma. ## METHODS. Treatment consist